CD23: an overlooked regulator of allergic disease.
Given the importance of immunoglobulin (Ig) E in mediating type I hypersensitivity, inhibiting IgE production would be a general way of controlling allergic disease. The low-affinity IgE receptor (FceRII or CD23) has long been proposed to be a natural regulator of IgE synthesis. In vivo research supporting this concept includes the observation that mice lacking CD23 have increased IgE production whereas mice overexpressing CD23 show strongly suppressed IgE responses. In addition, the finding that mice injected with monoclonal antibody directed against the coiled-coil stalk of CD23 have enhanced soluble CD23 release and increased IgE production demonstrates that full-length, trimeric CD23 is responsible for initiating an IgE inhibitory signal. The recent identification of ADAM10 (a disintegrin and metalloprotease) as the CD23 metalloprotease provides an alternative approach for designing therapies to combat allergic disease. Current data suggest that stabilizing cell-surface CD23 would be a natural means to decrease IgE synthesis and thus control type I hypersensitivity.
Conrad
Daniel H
DH
Department of Microbiology and Immunology, Virginia Commonwealth University, PO Box 980678, Richmond, VA 23298, USA. dconrad@vcu.edu
Ford
Jill W
JW
Sturgill
Jamie L
JL
Gibb
David R
DR
D000818:Animals; D000917:Antibody Formation; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology*; D007073:Immunoglobulin E / Q000378:metabolism*; D051379:Mice; D009154:Mutation; D017455:Receptors, IgE / Q000235:genetics / Q000502:physiology*
D017455:Receptors, IgE; D007073:Immunoglobulin E
Immunogenetics. 2004 Nov;56(8):564-71
15503007
Am J Respir Cell Mol Biol. 1999 Jan;20(1):1-8
9870911
J Exp Med. 2005 Sep 19;202(6):751-60
16172256
Nature. 1994 Jun 30;369(6483):753-6
8008068
J Immunol. 1998 Dec 15;161(12):6696-704
9862699
Am J Respir Crit Care Med. 2000 Mar;161(3 Pt 1):952-60
10712348
J Immunol. 2001 Sep 15;167(6):3139-45
11544299
J Allergy Clin Immunol. 2005 Oct;116(4):780-8
16210051
Am J Respir Crit Care Med. 1997 Dec;156(6):1945-55
9412579
Nat Rev Mol Cell Biol. 2005 Jan;6(1):32-43
15688065
Nat Immunol. 2006 Dec;7(12 ):1293-8
17072319
Annu Rev Immunol. 2003;21:579-628
12500981
J Immunol. 2006 Sep 1;177(5):2926-38
16920928
J Immunol. 1993 Mar 15;150(6):2372-82
8450218
Science. 1993 Aug 20;261(5124):1038-41
8351517
J Immunol. 2001 Apr 15;166(8):4863-9
11290762
Am J Physiol Gastrointest Liver Physiol. 2003 Jul;285(1):G223-34
12637252
Hybridoma. 1993 Feb;12(1):25-43
7681036
J Immunol. 2006 Apr 15;176(8):4811-7
16585575
J Immunol. 1999 Jul 1;163(1):217-23
10384119
J Immunol. 2003 Feb 15;170(4):1839-45
12574349
Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):753-7
1309956
Genes Immun. 2007 Apr;8(3):215-23
17301828
Int Immunol. 2007 Apr;19(4):545-56
17329233
Cell Immunol. 2006 Oct;243(2):107-17
17324389
Clin Rev Allergy Immunol. 2005 Aug;29(1):61-72
16222084
Biochem J. 1998 Aug 1;333 ( Pt 3):573-9
9677315
Int Immunopharmacol. 2002 Mar;2(4):453-61
11962725
Int J Immunopharmacol. 2000 Feb;22(2):131-41
10684997
Nat Biotechnol. 2000 Feb;18(2):157-62
10657120
Eur J Immunol. 1997 Dec;27(12):3228-35
9464810
J Immunol. 1994 Oct 1;153(7):3028-42
8089484
J Immunol. 2005 May 1;174(9):5612-9
15843560
J Immunol. 1999 Dec 1;163(11):5836-42
10570267
J Immunol. 1995 May 1;154(9):4240-6
7722284
J Biol Chem. 2003 Aug 29;278(35):32818-24
12801927
Scand J Immunol. 2006 Sep;64(3):177-84
16918684
Cell Immunol. 2005 Dec;238(2):123-34
16600195
Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6835-9
8041705
J Immunol. 1989 Jan 15;142(2):481-9
2521348
Eur J Immunol. 1998 Mar;28(3):1040-51
9541600
J Biol Chem. 2007 May 18;282(20):14836-44
17389606
J Biol Chem. 1998 Nov 27;273(48):31795-800
9822645
Gene. 1997 Mar 18;187(2):193-200
9099880
J Biol Chem. 2003 Aug 15;278(33):30469-77
12777399
J Immunol. 2004 Jan 15;172(2):1065-73
14707080
Structure. 2006 Jun;14(6):1049-58
16765898
Cell Immunol. 1997 Aug 25;180(1):36-46
9316637